Indications |
Oral Peptic ulcer Adult: 30 mg once daily in the morning given for 4 wk (duodenal ulcer) or for 8 wk (gastric ulcer). Hepatic impairment: Severe impairment: Max dose: 30 mg/day. Oral Hypersecretory conditions Adult: Initially, 60 mg daily and adjust as required. Daily doses >120 mg should be given in 2 divided doses. Hepatic impairment: Severe impairment: Max dose: 30 mg/day. Oral Acid-related dyspepsia Adult: 15-30 mg once daily in the morning for 2-4 wk. Hepatic impairment: Severe impairment: Max dose: 30 mg/day. Oral Gastro-oesophageal reflux disease Adult: 30 mg once daily in the morning for 4-8 wk. Maintenance: 15-30 mg once daily according to response. Child: and erosive oesophagitis: 1-11 yr: ≤30 kg: 15 mg once daily; >30 kg: 30 mg once daily. May increase doses up to 30 mg bid if patient is still symptomatic after 2 or more wk of treatment. 12-17 yr: For erosive oesophagitis: 30 mg once daily for up to 8 wk; For nonerosive gastro-oesophageal reflux disease: 15 mg once daily for up to 8 wk. Hepatic impairment: Severe impairment: Max dose: 30 mg/day. Oral NSAID-associated ulceration Adult: 15-30 mg daily for 4-8 wk. Hepatic impairment: Severe impairment: Max dose: 30 mg/day. Oral Prophylaxis of NSAID-induced ulcers Adult: 15-30 mg daily for 4-8 wk. Hepatic impairment: Severe impairment: Max dose: 30 mg/day. Oral H.pylori infection Adult: 1-wk triple therapy: 30 mg bid combined with clarithromycin 500 mg bid and either amoxicillin 1 g bid or metronidazole 400 mg bid. Hepatic impairment: Severe impairment: Max dose: 30 mg/day. Intravenous Erosive oesophagitis Adult: 30 mg over 30 minutes daily for up to 7 days. Hepatic impairment: Consider dose adjustment. Special Populations: Patients with severe hepatic impairment: Max dose: 30 mg daily. |
Warnings / Precautions |
Hepatic impairment. Gastric malignancy should be ruled out. Pregnancy and lactation. |
Adverse Reactions |
Diarrhoea, abdominal pain, nausea, constipation, headache, dizziness, eosinophilia, myalgia, glossitis, stomatitis, rash. |
Drug Interactions |
Reduced bioavailability with antacids and sucralfate. May decrease the absorption of atazanavir, itraconazole and ketoconazole. May increase plasma concentration of cilostazol. See Below for More lansoprazole Drug Interactions |
Mechanism of Actions |
Lansoprazole inhibits gastric acid secretion by inhibiting the H+/K+ ATPase, which is also known as the proton pump. Both basal and stimulated acid are inhibited. Absorption: Rapidly absorbed from the GIT (oral); peak plasma concentrations after 1.5 hr. Distribution: Protein-binding: 97%. Metabolism: Extensively hepatic; converted to 5-hydroxyl-lansoprazole and lansoprazole sulfone. Excretion: Via faeces (main) and urine (15-30% of a dose); 1-2 hr (elimination half-life). |
Administration |
Should be taken on an empty stomach. (Take before meals.) |
Storage Conditions |
Intravenous: Store at 25°C (77°F). Oral: Store at 25°C (77°F). |
ATC Classification |
A02BC03 - lansoprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD). |
Storage |
Intravenous: Store at 25°C (77°F). Oral: Store at 25°C (77°F). |
Available As |
|
Lansoprazole
Post Review about Lansoprazole Click here to cancel reply.
Lansoprazole Containing Brands
Lansoprazole is used in following diseases
Drug - Drug Interactions of Lansoprazole
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.